Qube Research & Technologies (QRT)’s Ovid Therapeutics OVID Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$209K	Buy	94,301 +40,350	+75%	+$72.1K	﹤0.01%	2944
2025 Q4	$87.9K	Buy	53,951 +28,674	+113%	+$44.2K	﹤0.01%	3205
2025 Q3	$32.9K	Sell	25,277 -47,464	-65%	-$41.1K	﹤0.01%	3234
2025 Q2	$24K	Buy	+72,741	New	+$21.9K	﹤0.01%	3241
2024 Q2	–	Sell	-54	Closed	-$165	–	4479
2024 Q1	$165	Buy	+54	New	+$181	﹤0.01%	4152
2022 Q1	–	Sell	-13,989	Closed	-$45K	–	2845
2021 Q4	$45K	Buy	+13,989	New	+$47.9K	﹤0.01%	2277
2020 Q2	–	Sell	-22,442	Closed	-$67K	–	1915
2020 Q1	$67K	Sell	22,442 -228,820	-91%	-$771K	﹤0.01%	1003
2019 Q4	$1.04M	Buy	+251,262	New	+$793K	0.03%	590

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Qube Research & Technologies (QRT)'s OVID Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Ovid Therapeutics (OVID) stake by 75% in Q1 2026, buying an estimated $72.1K and bringing the position to 94,301 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

Qube Research & Technologies (QRT) first reported a position in OVID in Q4 2019 and has held it in 8 quarters since. The position peaked at $1.04M in Q4 2019. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Qube Research & Technologies (QRT) held 94,301 shares of Ovid Therapeutics worth $209K as of Q1 2026.
Qube Research & Technologies (QRT) bought 40,350 Ovid Therapeutics shares in Q1 2026, an estimated $72.1K.
Ovid Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2944 holding.
Qube Research & Technologies (QRT) first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 8 quarters since.
Qube Research & Technologies (QRT)'s Ovid Therapeutics position peaked at $1.04M in Q4 2019.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.